Healthcare / BiotechnologyTaipei Exchange
$126.50
+0.50 (+0.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-363.4M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.0%
↓Gross Margin
N/A
•Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-444.8M · FCF $-377.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $32.3M | — |
| Net Income | $-444.8M | $-444.8M | $-422.7M | $-339.3M | $-288.5M |
| EBITDA | $-417.8M | $-417.8M | $-403.6M | $-325.5M | $-279.9M |
| EPS | — | — | -5.61 | -5.24 | -5.48 |
| Gross Margin | — | — | — | 100.0% | — |
| Operating Margin | — | — | — | -1077.4% | — |
| Net Margin | — | — | — | -1052.0% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.04 | 0.10 | — |
| Current Ratio | 33.99 | 33.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-377.3M | $-377.3M | $-363.4M | $-333.0M | $-278.4M |
| Returns | |||||
| ROE | -35.0% | -35.0% | -26.1% | -43.3% | -26.3% |
| Valuation | |||||
| P/B | 8.52 | 8.52 | 2.30 | 3.92 | — |
| Growth & Yield | |||||
| EPS Growth | — | — | -7.1% | 4.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+133.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.61 → n/d
Residual
+133.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.